摘要
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are the standard first-line option for non-small-cell lung cancer (NSCLC) harboring active EGFR mutations. The overall survival of patients with advanced NSCLC has improved dramatically with the development of comprehensive genetic profiles and targeted therapies. However, resistance inevitably occurs, leading to disease progression after approximately 10-18 months of EGFR-TKI treatment. Platinum-based chemotherapy is the standard treatment for patients who have experienced disease progression while undergoing EGFR-TKI treatment, but its efficacy is limited. The management of extensively pretreated patients with EGFR-mutant NSCLC is becoming increasingly concerning. New agents have shown encouraging efficacy in clinical trials for this patient population, including fourth-generation EGFR-TKIs, EGFR-TKIs combined with counterpart targeted drugs, and novel agents such as antibody-drug conjugates. We review current efforts to manage extensively pretreated patients with EGFR-mutant NSCLC.
学科与关键词
- Epidermal growth factor receptor-targeted therapy for the treatment of non-small cell lung cancer: a review of phase II and III trialsLu, Hong-Lian; Jie, Guang-Ling; Wu, Yi-Long*EXPERT OPINION ON EMERGING DRUGS, 2022, 27(2): 111-126.
- Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) combined with bevacizumab for advanced non-squamous non-small-cell lung cancer patients with gradual progression on EGFR-TKI treatmentYuman, Yu; Yuehong, Wang; Linying, Wu; Xuanli, Xu; Hua, Zhou; Qing, Wang; Jianying, ZhouMedicine; analytical reviews of general medicine, neurology, psychiatry, dermatology, and pediatries, 2021, 100(5): e23712.
- Combination of EGFR-TKIs with Chemotherapy versus EGFR-TKIs alone in EGFR-Mutant Advanced NSCLC with Concomitant Genetic AlterationsFeng, W.; Gu, W.; Zhang, H.; Lu, Y.; Gu, W.; Li, M.; Yang, S.; Zhang, J.; Ye, Z.; Lin, Q.; Liang, Y.; Chen, H.; Cheng, Y.; Yao, M.被引 1
